Tumor endothelial cell surface (Vascular compartment) (TEC surface)

The tumor endothelial cell surface within the vascular compartment refers to the specialized interface of blood vessels that infiltrate and support solid tumors. These tumor-associated endothelial cells (TECs) are phenotypically distinct from normal endothelial cells, exhibiting increased permeability, irregular morphology, and the overexpression of specific surface proteins such as Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), Endoglin (CD105), and Prostate-Specific Membrane Antigen (PSMA) [1][2]. This compartment is a primary target for anti-angiogenic therapies and vascular disrupting agents (VDAs), which aim to starve the tumor of essential nutrients and oxygen by inhibiting new vessel growth or inducing the collapse of existing ones [3]. Because these targets are located on the luminal surface of the vasculature, they are highly accessible to intravenously administered drugs, bypassing the high interstitial fluid pressure often found within tumor masses [4]. Therapeutic strategies include the use of monoclonal antibodies, small molecule kinase inhibitors, and ligand-directed toxins or radionuclides [5]. However, targeting this compartment can lead to systemic side effects such as hypertension and impaired wound healing due to the overlap with normal physiological endothelial functions [6].

Other names

Tumor vasculatureTumor-associated endothelial cellsTumor vascular endotheliumVascular compartment of tumorsTECs

The primary mechanisms of action for drugs targeting this compartment include the inhibition of pro-angiogenic signaling pathways (such as the VEGF/VEGFR axis), the disruption of the endothelial cell cytoskeleton to cause acute vascular collapse, and the use of antibodies to deliver cytotoxic payloads or induce immune-mediated destruction of the tumor vasculature.